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Abstract
Background: Toll like receptors (TLRs) play an important role in innate immunity and various studies suggest that
TLRs play a crucial role in pathogenesis of hepatitis B virus (HBV) infection. The present study aims in looking into
the status of crucial host and viral gene expression on inciting TLR7.
Methods: The transcription of TLR7 pathway signaling molecules and HBV DNA viral load were quantified by Real
Time-PCR after stimulation of TLR7 with its imiquimod based ligand, R837. Cell cycle analysis was performed using
flow-cytometry. Expression of TLR7 and chief cell cycle regulator governing G1/S transition, p53 was also seen in
liver biopsysss samples of CHB patients. HBV induced alteration in histone modifications in HepG2 cells and its
restoration on TLR7 activation was determined using western blot.
Results: The TLR7 expression remains downregulated in HepG2.2.15 cells and in liver biopsy samples from CHB
patients. Interestingly HBV DNA viral load showed an inverse relationship with the TLR7 expression in the biopsy samples.
We also evaluated the anti-viral activity of R837, an agonist of TLR7. It was observed that there was a suppression of HBV
replication and viral protein production upon TLR7 stimulation. R837 triggers the anti-viral action probably through the
Jun N-terminal Kinase (JNK) pathway. We also observed a downregulation of histone H3K9Me3 repression mark upon
R837 treatment in HBV replicating HepG2.2.15 cells, mimicking that of un-infected HepG2 cells. Additionally, the G1/S cell
cycle arrest introduced by HBV in HepG2.2.15 cells was released upon ligand treatment.
Conclusion: The study thus holds a close insight into the changes in hepatocyte micro-environment on TLR7 stimulation
in HBV infection.
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Background
Hepatitis B virus (HBV) infection is the leading cause of
liver cirrhosis and hepatocellular carcinoma (HCC);
however the outcome of the infection varies widely
among infected individuals [1]. Although various therap-
ies including alpha interferon and nucleoside/-tide
analogues are in use for treating HBV infection, a constant
effort is being made to develop more potential and cost ef-
fective drugs.
Innate immunity, the first line of defense, plays a vital
role in limiting the spread of pathogen after the initial
infection and triggers an effective adaptive immune
response. It has been seen that viral particles and its
components are sensed by pattern recognition receptors
(PRR), which include the RIG-I-like receptors (RLRs),
nucleotide oligomerization domain (NOD)-like receptors
(NLRs) and the toll-like receptors (TLRs). They subse-
quently activate an effective signaling pathway, which is
responsible for the production of antiviral cytokines.
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Though a clear role of adaptive immune response has
been seen in HBV clearance; the role of innate immunity
in HBV infection still remains enigmatic [2]. Earlier, it was
assumed that HBV was unable to induce an innate im-
mune response by acting as a ‘stealth virus’, which skillfully
evades the first line of defense and strategically block im-
portant candidates in its signaling pathway [3]. Therefore,
HBV remains undetected by the host immune surveillance
and infects the hepatocytes until the adaptive immunity is
triggered weeks later. However, on the contrary, HepaRG
cells as well as SCID mice harboring humanized liver,
shows an up-regulation of IFN (Interferon) response upon
HBV infection [4, 5]. Different TLR agonists have been
clinically assessed for treatment of chronic viral infections
like HBV, Hepatitis C virus (HCV) and Human Immuno-
deficiency Virus (HIV) [6]. Previous studies have shown
that TLR3, TLR4, TLR5, TLR7, and TLR9 ligands/agonists
when administered intravenously in HBV transgenic mice,
inhibits HBV replication [7]. In addition, a recent study
showed that activation of TLR2 is instrumental in
suppression of HBV replication in hepatoma cell lines and
woodchuck models [8].
Single stranded viral RNAs and synthetic compounds
like imidazoquinoline, loxoribine serve as agonists for
TLR7, which mainly operates through the Myeloid
Differentiation primary-response protein88 (MyD88)
dependent pathway. The subsequent messengers in the
signaling pathway activate different transcription factors
including Nuclear Factor kappa-light-chain-enhancer of
activated B cells (NF-КB), Jun N-terminal Kinase (JNK)
etc. that turns on the expression of downstream targets
and inflammatory cytokine secreting genes. In the
present study we have tried to look into the antiviral role
of TLR7 in hepatocyte microenvironment during HBV
infection. TLR7 exhibits viral clearance by modulating
several key host factors. Cell cycle analysis was carried
out to check the fate of HBV induced G1/S arrest on
TLR7 activation. We also investigated the epigenetic
alteration as a sequel to HBV infection and monitored a
partial reversal upon TLR7 agonist treatment implicating
an alteration of gene expression.
Method
Study subjects
A total of 19 liver biopsy samples were collected from
patients at Kalinga Gastroenterology Foundation
(Cuttack, Orissa, India) of which, 12 individuals had
chronic HBV infection. 7 biopsy samples were taken from
patients with steatosis but had no history of HBV, HCV or
HIV infections and they were taken as disease controls.
Signed informed consent was obtained from patients and
the study was approved by the institutional ethical commit-
tee. The diagnosis of patients with CHB was conformed
according to the AASLD guidelines 2009.
Cell culture
The maintenance and plating of hepatoblastoma cell
lines HepG2 and HepG2.2.15 was done as described pre-
viously [9].
Lamivudine treatment
Lamivir (Lamivudine tablets-150 mg) were provided by
Cipla. The tablets were suspended in sterile water and
then filtered using 0.2-μm filters. Cells were treated with
10, 20, 50 and 100 μM (final concentration) of Lamivudine
every day for 72 h as shown previously [10], after which
cells were harvested for further analysis.
Analysis of HBV viral properties
The synthetic ligand used for TLR7 was Imiquimod-
R837 provided by Invivogen. Cell culture supernatant
was collected from HepG2.2.15 cells after treatment with
4, 6 and 8 μg/ml of R837 for 72 h. Total DNA was ex-
tracted using Qiagen Blood mini-kit (Hilden, Germany).
HBV viral load in culture supernatant was quantified by
real-time TaqMan PCR assay using NIBSC standards as
described earlier [11]. HBeAg and HBsAg levels were
analyzed by using commercial ELISA kits (Diasorin,
S.P.A., Saluggia, Italy).
Chemical inhibitors
For pathway screening, HepG2.2.15 cells were stimu-
lated with 8 μg/ml of R837 (Invivogen, San Diego, CA,
USA) singly or in conjunction with various inhibitors.
10 μM NF-КB pathway inhibitor PDTC, 25 μg/mL of
SP600125 (MAPK/JNK pathway inhibitor), 2μMof
LY294002 (inhibitor of PI3K) and 10 μM SB203580
(MAPK/p38 pathway inhibitor) were used. They were
purchased from Sigma–Aldrich (St. Louis, MO, USA).
These inhibitors have specific targets and block the exact
pathways that they are chosen for [12].
RT-PCR analysis
For the RNA expression from HepG2 and HepG2.2.15
cells, 1x106 cells were plated in 6-well plate for the differ-
ent experiments. For the mRNA expression of TLR7, dif-
ferent cell cycle regulators and the different TLR7
signaling molecules from HepG2/HepG2.2.15 cells, total
RNA was treated with DNase and was reverse transcribed
with random hexamers using Revert Aid first-strand
cDNA synthesis kit (MBI Fermentas). Real time PCR was
performed in ABI 7200 SDS (Applied Biosystems, Foster
City, CA, USA) using Power SYBR Green (Applied Biosys-
tems). The target mRNA was relatively quantified and was
normalized to the internal control (GAPDH). The PCR
cycle number (CT) at which the exponential growth in the
fluorescence from the dye (SYBR Green) passes a certain
threshold was used to calculate the relative gene expression.
2-ΔΔCT was calculated to represent the relative
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quantification of the gene, where ΔCT (CT-target gene – CT-
GAPDH). ΔΔCT=ΔCT (Experiment) - ΔCT(Control). List of
primers used are listed in Table 1.
Western blot analysis
For western blotting, cells were harvested and lysed with
Laemelli buffer containing 120 mMTris-HCl (pH-6.8),
20% Glycerol and 4% SDS. Almost equal amounts of
protein were then run in a SDS PAGE and transferred
on Nitrocellulose membrane (Millipore). Following incu-
bation with primary antibody (overnight at 4 °C) and HRP
conjugated secondary antibody (3 h at room temperature),
the blots were developed using chemiluminescent sub-
strate (Millipore). Densitometry measurements of bands
were used for quantification of each marker by integrating
each peak in Image J software. List of primary antibodies
are listed in Table 2.
Confocal imaging to detect NF-КB nuclear translocation
HepG2.2.15 cells were grown on coverslips and treated
with R837 as stated earlier. The cells were washed thrice
with Phosphate buffered saline (PBS) and then fixed with
4% Paraformaldehyde (Sigma) in PBS for 10 min at
Table 1 List of primer sequences used for RT-PCR analysis
Gene FORWARD PRIMER REVERSE PRIMER
IRAK 1 5'-ACCGCAGATTATCATCAACC-3' 5'-AGACTTACAGCCATACTTCACT-3'
IRAK 4 5'-GCTGTATGTAGGGTGGAAAC-3’ 5'-TGCTGACAACTGGAAGGTAG-3'
TRAF6 5'-GCCCAGGCTGTTCATAGTTT-3' 5'-CAAGGGAGGTGGCTGTCATA-3'
p53 5’-CCCAAGCAATGGATGATTTGA-3’ 5’-GGCATTCTGGGAGCTTCATCT-3’
CYCLIN D1 5’-AGCTCCTGTGCTGCGAAGTGGAAAC-3’ 5’-AGTGTTCAATGAAATCGTGCGGGGT-3’
CYCLIN E 5’-CAGCACTTTCT TG AGCAACACCCTC-3’ 5’-TCTCTAT GTCGCACCACTGATACCC-3’
CYCLIN B1 5’-AAGAGCTTTAAACTTTGGTCTGGG-3’ 5’-CTTTGTAAGTCCTTGATTTACCATG-3’
CYCLIN A 5’GCATGTCACCGTTCCTCCTT-3’ 5’CAGGGCATCTTCACGCTCTAT-3’
JNK 5'- GTACTTGTATGAAACCACCTTTCT -3' 5'- AGCATCTCTTTCTGAATCTATGAAG -3'
PI3KCA 5'- AAGGGTGCTAAAGAGGAACAC -3’ 5'-CATGAGGTACTGGCCAAAGAT -3'
PI3KCB 5'- CTCCAAATGTTGCGCTTGATG -3' 5'- ACAACTTCAATGAGGCCAGAG -3'
PI3KCG 5’- CACCGAGACAGGAAACCTATTT -3’ 5’- TAGCACAAATGGCACTCTCTC -3’
NF-КB 5’-CGCATCCAGACCAACAACA-3’ 5’- TGCCAGAGTTTCGGTTCAC-3’
p38 5’- TCTGCTTACCCTTCACCTTTG -3’ 5’- CACATCCTCACTCTGCTAGAAAT -3’










Table 2 List of Antibodies used




Anti-H3K4Me3 39159 ACTIVE MOTIF
Anti-H3K9Me3 39161 ACTIVE MOTIF
Anti-H3K27Me3 39155 ACTIVE MOTIF
Anti-H3K18Ac 39587 ACTIVE MOTIF
Anti-H3K9Ac MILLIPORE,07-352
Anti-NFКBp65 14-6731-81 e-BIOSCIENCE
Anti-p53 SC-126 SANTA CRUZ
BIOTECHNOLOGY
Anti-Mouse IgG-HRP W402B PROMEGA
Anti-Rabbit IgG-HRP A1949 SIGMA
Anti-Rabbit Alexa Fluor A11034 INVITROGEN
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room temperature (RT). Cells were washed thrice with
PBS and permeabilized with 1% Triton X-100 in PBS for
10 min at RT, washed with PBS thrice followed by blocking
with 3% BSA in PBS for 1 h at RT. Cells were incubated
with Anti-NFКB (eBioscience) for 1 h at RT, washed thrice
with PBST (PBS + 0.05% Tween20) and then incubated
with secondary antibody (Alexa-Fluor anti-rabbit 488, Invi-
trogen) for 1 h in dark at RT, followed by three washes with
PBST. Coverslips were mounted with mounting media con-
taining DAPI (Sigma Aldrich). Fluorescence for Alexa and
DAPI was visualized with Nikon Ti-E confocal microscope
with A1RMP scanner head equipped with Nikon imaging
software (NIS).
Cell cycle analysis
For cell cycle analysis, the cells were harvested and thor-
oughly re-suspended in Phosphate Buffered Saline (PBS).
The cells were then fixed by adding double volume of
chilled 70% ethanol (Merck) drop wise, with continuous
vortexing. After incubating the mixture overnight at
−20 °C, it was spinned and the cells were resuspended in
500 μl of PBS. The cells were then incubated with
RNaseA (0.2 mg/ml) for 30 min followed by Propidium
Iodide (50 μg/ml) (Sigma) at 37 °C for 1 h. Flow cyto-
metric data acquisition was performed on BD FACS
Calibur platform.
MTT assay
Cell proliferation was measured by MTT assay (Cell
Titer 96® AQueous One Solution Cell Proliferation
Assay, Promega, USA) as described previously [9]. The
cells were uniformly seeded in each well of 96-well
plates and grown in RPMI 1640 supplemented with 10%
FBS. After 24 h, the media was removed and replaced
with fresh media and treated with R837. The plates were
incubated at 37 °C in a humidified atmosphere of 5%
CO2 for 72 h. At indicated time-points, relative cell num-
bers were determined by incubating cells with MTT3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide.
The absorbance at 490 nm is directly proportional to
the number of viable cells. All experiments were
performed in triplicates.
Results
Reduced TLR7 expression during HBV infection
Our previous studies have showed that TLR7 mRNA
expression is highly compromised in HBV replicating
HepG2.2.15 cells when compared to the HepG2 cells [9].
It is believed that HBV represses the innate immune re-
sponse during a natural infection. Thus, it was expected
that TLR7 expression would be re-established on viral
elimination. We therefore, wanted to check the TLR7
expression of HepG2.2.15 cells on administration of a
common nucleoside analogue (Lamivudine). It was seen
that TLR7 expression showed a gradual increase on
treatment of HepG2.2.15 cells with Lamivudine in a dose
dependent manner (20 μM, 50 μM and 100 μM). The
doses of lamivudine were used previously where HBV
mutants were subjected to drug susceptibility assay in
vitro [10]. HepG2 cells taken as control, did not show
changes in TLR7 expression on Lamivudine treatment
(Fig. 1a i and ii). We also showed a significant suppres-
sion of HBV DNA viral load on Lamivudine treatment
(Fig. 1b). This broadly indicated that HBV viral load was
inversely proportional to the TLR7 expression. Small-
scale preliminary study also showed that TLR7 expres-
sion was downregulated in liver biopsy specimens from
chronic HBV patients (LB_7-18) (n = 12) compared to
control steatosis individuals (LB_1-6) (n = 6) (Fig. 1c).
The viral and clinical parameters of the patients are also
listed (Fig. 1d). Interestingly, while analyzing the TLR7
expression in liver biopsy specimens, it was seen that the
HBV viral loads in the biopsies showed an inverse rela-
tionship with the TLR7 expression status. Liver biopsy
samples LB_8, LB_13, LB_15, LB_16, LB_18 exhibiting
high viral loads had lower TLR7 levels. We thus wanted
to investigate whether inciting TLR7 with its specific lig-
and could help in reduction of viral components.
Suppression of HBV replication upon TLR7 activation in
HepG2.2.15 cells
R837 activates a MyD88-dependent TLR7 pathway and
leads to the induction of different transcription factors,
including NF-КB. To confirm the stimulation of TLR7
with its ligand imidazoquinoline (R837), the expression
of chief down-stream molecules belonging to the TLR7
pathway were checked post treatment. Stimulation led
to increased expression of the different pathway regula-
tors (NF-КB, p38, JNK). However, PI3K expression did
not show a significant change on TLR7 stimulation
(Fig. 2a). Chief antiviral cytokines (IFN-α, IFN-β, TNF-α
and IL-6) which are associated with HBV clearance were
also upregulated on TLR7 stimulation (Fig. S1A). Stimu-
lation of TLR7, promoted proteolytic degradation of the
inhibitor I-КB and allowed nuclear translocation of
Nuclear Factor-КB p65 subunit from the cytoplasm of
the cells (Fig. 2b). Interestingly, the protein expression
of NF-КB is greatly compromised in HepG2.2.15 cells
compared to HepG2 cells (Fig. 2c), the levels of which
are substantially restored upon TLR7 activation (Fig. 2d).
In an attempt to address the effect of TLR7 activation in
HBV replication, HepG2.2.15 cells were treated with 4, 6
and 8 μg/ml of R837 for 72 h and there was a significant
decrease in HBV DNA viral load (Fig. 3a) and viral pro-
tein (HBsAg and HBeAg) concentration (Fig. 3b) in a
dose dependent manner in the culture supernatant upon
treatment with ligand.
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TLR7 agonist suppresses HBV replication through JNK
pathway
A look at the signaling cascade involving TLR7 is
depicted in Fig. 4a. In order to identify the pathway
through which TLR7 executes its anti-viral effect, we tar-
geted and inhibited some key molecules essential in each
of these pathways (JNK, p38, PI3K and NF-КB) in pres-
ence of R837. HBV DNA load was maximal when the
JNK pathway was blocked with SP600125 even when
TLR7 was stimulated as compared to the other blockers
PDTC, LY294002 and SB203580 which blocked NF-КB,
PI3K and p38 pathway respectively (Fig. 4b). These
blockers have specific targets and retards definite
signaling pathways. Our findings thus suggest that JNK
pathway blocker SP600125 impedes the antiviral action
of R837. Increased viral protein expression (HBsAg and
HBeAg) on using SP600125 substantiates the observa-
tion, that TLR7 agonist shows its antiviral action
through the JNK pathway (Fig 4C). The host cytokine
profile (chiefly associated with HBV clearance) was mon-
itored in presence of protein blockers in combination
with R837 in order to identify the cytokines responsible
for viral suppression. The expression of antiviral cyto-
kines including IFN-β, TNF-α, IL-1β, IL-6 and IL-10 was
substantially repressed on blocking JNK pathway with its




Fig. 1 TLR7 expression remains compromised in HepG2.2.15 cell lines. The expressions are significantly re-established on viral elimination. TLR7 expression
of HBV infected subjects is downregulated compared to disease control steatosis patients and is also inversely related to the HBV DNA load in liver biopsy
samples. a TLR7 mRNA expression of HepG2.2.15 cells is regained on treatment with Lamivudine, a potent nucleoside analog reverse transcriptase inhibitor,
at different doses (20, 50 and 100μM). a TLR7 mRNA expression of HepG2 cells taken as control after treatment with Lamivudine shows no change. b TLR7
expression in HepG2.2.15 cells on treatment with different doses of Lamivudine. b HBV DNA viral load is suppressed on treatment of Lamivudine in a dose
dependent manner. c The mean TLR7 expression of the control subjects was arbitrarily set as 1. The fold change of TLR7 expression in each of the patients
was then evaluated. Increased TLR7 expression of liver biopsy specimen of control subjects with steatosis (LB_1-6) compared to HBV infected patients
(LB7_18) along with clinical and virological parameters of the patients. Box and Whisker Plot was used to score the TLR7 expression. d Viral and clinical
parameters of the patients
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α and IFN-γ showed no significant downregulation
(Additional file 1: Fig. S1b). Thus, the cytokines IFN-β,
TNF-α, IL-1β, IL-6 and IL-10 probably play a crucial
role in HBV suppression on TLR7 activation. R837 mod-
ulates the key components of signal transduction path-
way of host cells and implicate a broad-spectrum
function of this agonist in its ability to modulate mul-
tiple cellular functions.
TLR7 stimulation exerts an alteration in host epigenetic
signatures in HepG2.2.15 cells
We have monitored that TLR7 activation affects the
transcription of multiple downstream targets including
NF-КB, p38 and JNK. All these proteins are important
hubs of signal transduction pathway and can execute
pleiotropic effects. We have observed antiviral response
of TLR7 is majorly triggered through the JNK pathway.
We thus wanted to monitor the alteration of expression
of several JNK downstream targets following TLR7 acti-
vation. Interestingly, JNK responsive gene c-Jun showed
prominent increase in transcription unlike SAP-1 whose
expression is in a JNK independent manner. Other JNK
responsive genes like c-Myc and Elk-1 [13] showed mar-
ginal changes (Fig. 4d), indicating that the antiviral re-
sponse although majorly steered through JNK pathway,
is mostly gene specific.
Since TLR7 activation upregulates the expression of dif-
ferent downstream regulators, we wanted to understand
its role, affecting the transcription of chromatin template.
In order to assess that, the global alteration of selective
histone modification including H3K4Me3, H3K9Me3 and
H3K9Ac, was quantified in HepG2.2.15 cells following
R837 treatment (Fig. 5a). While the activation signatures
(H3K4Me3, H3K36Me3 and H3K9Ac) did not show a sig-
nificant change, alteration in H3K9Me3 repression mark
was noteworthy which indicates a de-repression scenario
where active transcription was re-established. A compari-
son of these epigenetic signatures between HepG2 and
HepG2.2.15 cells was further carried out and H3K9Me3
level, unlike other marks, showed an increased expression
in the latter cell line (Fig. 5b). Thus, upon HBV infection
host transcription would preferably halt which is evident
Fig. 2 TLR7 pathway is activated on stimulation with its specific ligand imiquimod, R837. Chief downstream regulators, especially NF-ĸB is
activated and transclocated to the nucleus on TLR7 activation. a Host immune response on TLR7 activation, using TLR7 ligand. HepG2.2.15 cells
were treated with TLR7 agonist, R837 (8μg/ml) for 3 days. mRNA expression of different downstream regulators (NF- КB, JNK, p38 and PI3K)
involved in the TLR7 pathway. b Confocal imaging showing nuclear uptake of Nuclear Factor-КB p65 subunit (NF- КB) from cytoplasm in cells
where HepG2.2.15 cells are taken as control and HepG2.2.15 cells stimulated with TLR7 ligand, R837 (8μg/ml) for 72 h. c Nuclear Factor-КB p65
subunit (NF-КB) protein expression of HepG2 and HepG2.2.15 cells. d Nuclear Factor-КB p65 subunit (NF- КB) protein expression of HepG2.2.15
cells taken as control and treated with R837 (8μg/ml) for 72 h
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from the epigenetic change. This repression is again res-
cued upon TLR7 activation implicating that R837 has an
ability to affect the cellular microenvironment thereby re-
establishing transcription activation status. Thus the HBV
induced alteration of host epigenetic status implicates a
novel role of this ligand in regulating cellular transcription
profile of host cell.
TLR7 activation results in the release of G1/S cell cycle
arrest in HepG2.2.15 cells
The alteration of epigenetic signature in HepG2.2.15
cells as a sequel to R837 treatment implicates a broad-
spectrum effect in host cell milieu. We further investi-
gated whether TLR7 activation might influence the host
cell cycle stages. It has been shown previously that HBV
transformed cell line HepG2.2.15 undergoes a G1/S
arrest. This arrest is induced by the virus and results in
slow proliferation of the cells [14]. Since TLR7 activation
reduces the HBV DNA viral load, we wanted to find out,
whether this would affect the status of G1/S arrest
within the cells. It was observed that reduction of HBV
infection induced a release in the G1/S arrest (Fig. 6a).
The percentage of cells in the different phases of cell
cycle was determined in HepG2.2.15 cells before and
after the treatment with R837 (Fig. 6b). The proportion
of cells in G1 phase was maximal compared to S and
G2/M phases in HepG2.2.15 cells. A distinct G1/S arrest
in the cell cycle of the HepG2.2.15 cells was observed.
To assess the antiviral action of R837, we checked the
proportion of cells in different phases of the cell cycle
on TLR7 activation. The quantity of cells in the G1
phase showed significant reduction, when the cells were
treated with R837. The cells apparently entered the S
phase after a G1 escape. Thus, a distinct release in the
cell cycle arrest in HepG2.2.15 cells was observed after
treatment. To investigate the mechanism of G1 phase
arrest induced by HBV and subsequent release in arrest
after TLR7 activation, the expression of cell cycle regula-
tors was studied. It was expected that the dynamics of
transition of different phases of cell cycle would corrob-
orate with expression of cell cycle genes. p53 is the key
regulator in the transition from G1 to S phase and is
upregulated in virus infected cells [15]. In this connec-
tion it was observed that mRNA expression of p53
remains upregulated in liver biopsy samples of chronic
HBV patients (n = 8) as compared to steatosis patients,
serving as disease control (n = 7) (Fig. 6c). Further,
treated cells showed a reduced mRNA and protein ex-
pression of p53 compared to the untreated HepG2.2.15
cells (Fig. 6d, 5B). Cyclin D1 is also required for G1/S
cell cycle transition and remains upregulated in
HepG2.2.15 cells compared to HepG2 cells (16). TLR7
activation led to a downregulated expression of Cyclin
D1 transcript indicating the role of TLR7 in viral reduc-
tion. Cyclin E, another crucial regulator of G1/S transi-
tion, remains downregulated in infected cells [16]. It was
seen that mRNA expression of Cyclin E was significantly
upregulated in treated cells (Fig. 6d) implicating a p53-
independent cell cycle regulatory pathway upon TLR7
activation. Since the proportion of cells in G2/M transi-
tion was not affected after treatment, it was expected
that the regulators too would not show significant
modulation. Our findings showed, that the cell cycle reg-
ulators CyclinB1 and A, which play crucial role in G2/M
and late S into late G2 phase transition respectively, had
no significant changes in treated and untreated
HepG2.2.15 cells (Fig. 6d). Further, MTT assay showed
that treatment of HepG2.2.15 cells with R837 at different
time points had no significant cytotoxic affects and on
the contrary promoted cell growth (Fig. 6e). MTT assay
clearly showed that there was no significant cell death
due to R837 treatment.
Discussion
TLRs have a pivotal role in the regulation of innate im-
mune responses and are intricately associated with the
host defense mechanism. TLR activation leads to the
production of endogenous interferons and antiviral cyto-
kines, which establishes a crosstalk between innate and
adaptive immune responses. This triggers the immune
effector cells, which plays a vital role in the antiviral
immunity. Studies show that modulation of TLR
Fig. 3 HBV titre was evaluated in culture supernatants of HepG2.2.15
cells after treatment with 4, 6 and 8μg/ml of TLR7 agonist (R837) for
72 h. a HBV DNA was isolated from the culture media of R837 treated
cells and the load was assessed by absolute real-time PCR using WHO
standards. b HBsAg and HBeAg were detected from the culture
supernatant of treated cells by ELISA
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signaling pathways can be effective in controlling infec-
tious diseases, immune-related disorders and cancers
[17]. It has been seen previously that the innate immune
response remains suppressed on HBV infection [18]. In
the current study, we have shown that TLR7 expression
is reduced in liver biopsy samples of Chronic Hepatitis B
patients compared to steatosis individuals serving as dis-
ease controls. Patients with steatosis have been earlier
used as disease control for HBV-related innate immune
studies [19]. We have also showed that the compromised
TLR7 expression in HepG2.2.15 cells was significantly
re-established when HBV replication was suppressed by
use of a common nucleoside analogue (Lamivudine),
thus further proving that HBV suppresses TLR7. Lami-
vudine is a currently approved licensed anti-HBV drug
which results in decrease in the circulating HBV DNA
levels [20]. Previous studies have showed that Lamivudine
significantly inhibited levels of HBV DNA in HepG2.2.15
cell line [21]. This observation was further confirmed,
since there was no significant change in TLR7 expression
in HepG2 cells taken as control.
Our previous studies have shown that both TLR7 and
miR-155 are down-regulated and positively correlate
with each other in HBV infection and ectopic expression
of miR-155 can reduce HBV viral load through targeted
suppression of C/EBP-β [9]. Thus, possibly, stimulation
of TLR7 might as well exhibit an anti-viral effect. There-
fore, we aimed to explore the effect of TLR7 stimulation
on HBV replication in hepatocyte micro-environment.
Our findings show that TLR7 activation leads to sup-
pression of HBV replication and viral protein (HBsAg
and HBeAg) production, which is in concordance to a
previous study that was conducted in Chimpanzees [22].
This study takes a step forward in identifying the differ-
ent host factors and the alterations in gene expression
on TLR7 activation in virus infected hepatocytes. An
earlier report showed that MAPK/ERK and PI3K/AKT
pathways were responsible for the suppression of HBV
replication through TLR2 stimulation [8], however no
such studies were conducted with TLR7. In the current
study, we found that the antiviral action of TLR7 takes
place through the JNK pathway. JNKs are subgroups of
MAP kinases and are activated in response to cytokines,
TLRs and antigen receptors like T and B cells [23]. Acti-
vated JNKs phosphorylate c-Jun, JunD, ATF and other
transcription factors, which is involved in the formation
Fig. 4 TLR7 mediated cellular signaling pathway in suppression of HBV replication. HepG2.2.15 cells were pretreated with or without different
pathway inhibitors (NF-КB pathway inhibitor PDTC, MAPK/JNK pathway inhibitor SP600125, PI3K-AKT inhibitor LY294002 and MAPK/p38 pathway
inhibitor SB203580). After 1 h incubation, R837 was treated for 6 h. a Schematic representation of TLR7 signaling pathway and important
inhibitors of relevant signaling molecules. b and c. HBV DNA, HBsAg AND HBeAg from culture supernatants on stimulation with R837 alone or pre-treated
with different pathway inhibitors detected by real time RT- PCR and ELISA. d. Relative mRNA expression of JNK–dependent/ independent responsive genes
(c-Jun, c-Myc, Elk-1 and SAP-1)
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and activation of AP-1 complex. C-jun is a downstream
molecule phosphorylated by the JNKs and is a well-
characterized oncogene, found in the liver [24]. Results
showed that there was an increased expression of c-jun
on TLR7 stimulation, indicating the activation of JNK
pathway and its possible role in the anti-viral response.
Further, it was seen that blocking JNK pathway with
SP600125, curbed the expression of different cytokines
including IFN-β, TNF-α, IL-1β, IL-6 and IL-10. Chief
anti-inflammatory cytokine IL-10 and pro-inflammatory
cytokines IL-6 and TNF-α probably play a balanced role
in viral elimination. The blockers that have been used
for pathway screening have specific roles and act specif-
ically on different substrates. Previously, several cyto-
kines have been shown to have a HBV suppressive effect
in infected transgenic mice and cell line models. Several
cytokines viz. IL-12, IL-18 and IFNs have been shown to
have a suppressive effect in HBV-infected transgenic
mice [25–27]. Another study had shown that IFN-γ syn-
ergistically acts with TNF-α and inhibits expression of
HBV RNA levels in immortalized hepatocyte cell line
(HBV-MET) [28]. IL-4 has also been shown to be an ef-
fective cytokine in viral protein suppression in Hep3B
cell line [29]. Although the above-mentioned cytokines
may play vital roles in HBV suppression, there may be
multiple modes by which HBV is eliminated on TLR7
activation. Further studies are required to elucidate the
exact pathway responsible in HBV clearance on trigger-
ing TLR7.
Eukaryotic genome is packaged into chromatin, which
is subjected to dynamic structural alteration [30]. Post-
translational modification (PTM) of core histone tails
regulates gene expression spatiotemporally [31]. Site
specific histone modifications can be read by effector
proteins which delineate a specific cellular fate as
highlighted through histone code hypothesis [30].
H3K4Me3 and H3K9Me3 are the transcription activa-
tion and repression signatures respectively. H3K9Ac also
positively regulates transcription. Thus the global alter-
ations of these epigenetic signatures reflect a major
variation in cellular gene expression profile. Dynamic
chromatin architecture is perturbed due to viral infec-
tion and an alteration of host posttranslational modifica-
tion; fewer studies have embarked onto changes in host
genome. Remarkably, Telbivudine, an anti HBV drug
dramatically restores histone H3K4Me3 and H3K27Me3
of HepG2.2.15 cells akin to HepG2 cells [32]. Detailed
investigation of host epigenetic changes as a sequel to
TLR7 activation showed global repression of H3K9Me3
levels (Fig. 5a). This indicates a transcription de-
a
b
Fig. 5 Status of epigenetic markers and transcription factors on TLR7 activation. HepG2.2.15 cells were treated with R837 for 72 h and then the
cells were subjected to Western Blot for protein expression studies. a Protein expression of different histone modifications (H3K4Me3, H3K9Me3,
H3K36Me3 and H3K9Ac) and p53 before and after TLR7 activation. b The relative expression of the proteins (H3K9Me3 and p53) in HepG2 and
HepG2.2.15 cells
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repression scenario. Indeed we have seen upregulation
of JNK responsive transcripts upon R837 treatment
(Fig. 6a). This effect is however gene specific in broad
perspective. Treatment of R837 to HepG2.2.15 cells re-
versed the epigenetic markers as well as transcription
factor levels similar to HepG2 cells implicating that
TLR7 activation possibly leads to viral reduction through
suppression of HBV replication. These results further
raise a possibility that antiviral response can be mani-
fested by targeting the histone PTMs gene specifically
and hence can be used as an epigenetic therapy.
Previous studies show Hepatitis B undergoes slow cell
proliferation and induces a G1/S cell cycle arrest in
HepG2.2.15 cells [16]. It is worth mentioning that HBx
performs a dual activity of anti-proliferation and transac-
tivation in HCC tissues. The study further showed that
the effect of HBx on cell viability probably depends on
the balance between pro-apoptotic and anti-apoptotic
effects of NF-КB on different cell types [33]. Thus, the
wild type HBx is responsible for the late G1 arrest, and
upon TLR7 activation this arrest is partially released.
The viral infection also triggers an upregulated
expression of p53, which successfully retards the transi-
tion from G1 to S phase and prevents cell growth. The
elevated p53 expression in liver biopsy samples of CHB
patients re-affirmed the G1/S arrest induced by the
virus. Previous studies have shown that serum p53 levels
are higher in HBV- related cirrhotic patients compared
to chronic HBV ones [34]. Interestingly, apart from al-
teration of p53 levels, Cyclin D1 and Cyclin E levels
were dramatically modulated upon TLR7 activation im-
plicating a role of p53 independent pathway regulating
cell cycle. Thus, R837 treatment partially restores the
cell cycle stages by removing the G1/S arrest and thus
the antiviral response could be reestablished. No signifi-
cant cell death was observed in the MTT assay. There
was a clear indication of cell proliferation and there was
increase in cell number at different time points on R837
treatment. The study on role of TLR7 in HBV infection
has been shown in HepG2.2.15 cell line, harboring mul-
tiple copies of HBV genome, since the supernatant from
the cell culture can infect chimpanzees intravenously,
showing typical symptoms of human hepatitis, highlight-
ing the efficiency of the model. Further, HepG2.2.15 cells
Fig. 6 Flow cytometric analysis and alteration of key cell cycle regulators upon TLR7 activation. HepG2.2.15 cells were treated with R837 (8μg/ml)
for 72 h and then subjected to flow cytometric analysis to study the status of G1/S arrest. a Cell cycle analysis by FACS. b Percentage of cells in
different phases of cell cycle before and after TLR7 activation. c p53 expression in liver biopsy samples of chronic HBV patients compared to
control steatosis patients. d Relative mRNA expression of different cell cycle regulators (p53, Cyclin E, Cyclin D1, Cyclin B1 and Cyclin A) on R837
treatment. e Detection of invitro cell proliferation on TLR7 activation using MTT assay. HepG2.2.15 cells were treated with R837 for 72 h and then
incubated with MTT at the indicated time points
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have been used to study the pathogenesis of HBV and in
elucidating the role of anti-viral drugs in HBV-related
disorders [35–39]. Nevertheless, TLR7 levels and its role
in HBV pathogenesis should be looked into other
relevant systems like PHH cultures or NTCP-driven in
vitro infection of different cell lines.
Conclusion
The study thus shows that TLR7 plays a anti-viral role
in HBV infection and holds a promising immuno-
modulatory therapeutic value against this hepato-
tropical viral disease.
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